| Literature DB >> 17892356 |
Rachel Morra1, Mona Munteanu, Françoise Imbert-Bismut, Djamila Messous, Vlad Ratziu, Thierry Poynard.
Abstract
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and a better benefit-to-risk ratio than biopsy of five combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive, Paris, France) in patients at risk of chronic liver diseases: FibroTest (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest (BioPredictive) for the quantitative assessment of steatosis; ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity in chronic viral hepatitis C and B; NashTest (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTest for the quantitative assessment of alcoholic steatohepatitis (also known in the USA as HCV-FibroSURE, HBV-FibroSURE, ASH-FibroSURE and NASH-FibroSURE; LabCorp, NC, USA). The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17892356 DOI： 10.1586/14737159.7.5.481
Source DB: PubMed Journal: Expert Rev Mol Diagn ISSN： 1473-7159 Impact factor: 5.225